ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Calcineurin"

  • 2022 American Transplant Congress

    Impact of Biliary Reconstruction on Tacrolimus Absorption in Pediatric Liver Transplant

    M. Chandran1, D. Yoeli1, A. Sater2, M. Adams1, F. Karrer1

    1Children's Hospital Colorado, Aurora, CO, 2University of Colorado, Aurora, CO

    *Purpose: Tacrolimus (FK506) oral bioavailability in pediatric liver transplant recipients (LTR) is poor. Enteral FK506 is primarily absorbed in the small intestine and subject to…
  • 2022 American Transplant Congress

    Post-Kidney Transplant Dementia Risk by Modifiable Risk Factors and CNIs Among Older Recipients

    Y. Chen1, J. Ahn1, N. Chu1, S. Bae1, M. A. Schnitzler2, G. Hess3, K. Lentine4, D. Segev5, M. McAdams-DeMarco1

    1Johns Hopkins School of Medicine, Baltimore, MD, 2Surgery, Saint Louis University, O Fallon, IL, 3Drexel University School of Medicine, Philadelphia, PA, 4Saint Louis University, St. Louis, MO, 5Johns Hopkins University, Baltimore, MD

    *Purpose: Up to 17% of older recipients develop dementia after kidney transplant (KT). While there are known modifiable risk factors for dementia among community-dwelling older…
  • 2022 American Transplant Congress

    Evaluation of Different Initial Tacrolimus Dosing Regimens in Pediatric Post-Liver Transplantation

    A. F. Alghanem1, A. Alsmari1, H. Joharji2

    1Pharmaceutical Care, King Abdulaziz Medical City, Riyadh, Saudi Arabia, 2Pharmaceutical Care, King Faisal Specialized Hospital and Research Center, Riyadh, Saudi Arabia

    *Purpose: Tacrolimus is an immunosuppressant used in post-liver transplantation, has wide pharmacokinetic variability, particularly in pediatric patients. Therefore, this study aimed to evaluate different weight-based…
  • 2022 American Transplant Congress

    Long-Term Outcomes After Conversion to a Belatacept-Based Immunosuppression in Kidney Transplant: A Matched Cohort Study

    G. Divard, C. Debiais, C. Legendre, O. Aubert, C. Lefaucheur, A. Loupy

    Paris Transplant Group, INSERM, Paris, France

    *Purpose: Conversion to belatacept after transplant seems to be safe. However, no studies have reported the long-term efficacy and safety outcomes after conversion to belatacept…
  • 2022 American Transplant Congress

    Predicted Performance of Bayesian-Based Precision Dosing Software for Tacrolimus

    A. Seghezzo1, J. Kerr1, A. Gupta2, A. Ta2, L. Powell2, A. Feist3

    1University of California San Diego Health, San Diego, CA, 2PrecisePK, San Diego, CA, 3UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences, San Diego, CA

    *Purpose: Bayesian-based precision dosing software (BPDS) has been utilized for therapeutic drug monitoring to optimize medication use. However, BPDS for tacrolimus (TAC) is not routinely…
  • 2022 American Transplant Congress

    Conversion to Everolimus-Based Immunosuppression Regimen with Calcineurin Inhibitor Reduction Ameliorates Histological Damage in Kidney Transplant Recipients with Calcineurin Inhibitor-Induced Nephrotoxicity

    K. Hotta, N. Iwahara, T. Tanabe, N. Shinohara

    Hokkaido University Hospital, Sapporo, Japan

    *Purpose: In the last two decades, the short-term results for kidney transplantation (KTX) have improved owing to the use of calcineurin inhibitors (CNIs). However, long-term…
  • 2022 American Transplant Congress

    Kidney Transplant Recipients Not Reaching the Expected Post-Transplant Creatinine Range Most Likely Show Calcineurin-Inhibitor Nephrotoxicity Upon Histology

    S. von Moos1, K. Valkova1, L. Matter1, T. F. Müller1, T. Schachtner2

    1University Hospital Zürich, Zürich, Switzerland, 2University Hospital Zurich, Zürich, Switzerland

    *Purpose: Very recently, our own data suggested that approximately 25% of deceased-donor kidney transplant recipients (KTRs) and 10% of living-donor KTRs don’t reach the expected…
  • 2022 American Transplant Congress

    Impact of Early Calcineurin-Inhibitor Conversion to Belatacept on Renal Allograft Function in a Steroid-Free Maintenance Regimen: Results from a Randomized Controlled Study

    I. Tawhari1, P. Hallak1, S. Hartzell2, V. Mas3, P. Cravedi2, J. Leventhal1, J. Ansari1, L. Gallon1

    1Northwestern University, Chicago, IL, 2Mount Sinai, New York, NY, 3University of Maryland, Baltimore, MD

    *Purpose: Belatacept (Bela) was developed to minimize nephrotoxicity and cardiovascular risk associated with Calcineurin inhibitors (CNIs). Early steroid withdrawal (ESW) and simultaneous CNI avoidance (CNIA)…
  • 2022 American Transplant Congress

    The Successful Use of De Novo Belatacept with Reduced Dose Tacrolimus to Mitigate the Risks of Delayed Graft Function in Kidney Transplantation

    E. Siskind1, J. Splinter1, C. Taing1, A. Adekile2, S. Njim1, S. Shah1, R. Plews3, D. Conti4, S. Patel2

    1Center for Transplantation, University Medical Center of Southern Nevada, Las Vegas, NV, 2University Medical Center of Southern Nevada, Las Vegas, NV, 3Center for Transplantation, Albany Medical Center, Albany, NY, 4Albany Medical Center, Albany, NY

    *Purpose: The new kidney allocation system has caused increased organ travel times and therefore increased cold ischemia time. Furthermore, the change in the priority to…
  • 2022 American Transplant Congress

    Meta-Analysis of the Chronic Exposure to Calcineurin Inhibitors and the Risk for Chronic and End-Stage Kidney Disease in Non-Renal Solid Organ Transplant Recipients

    A. Alvarez Elias1, M. Riedl1, D. Stewart2, A. Ruco3, P. Bobos3, S. Maharaj4, V. Shah5, E. Uleryk6, C. Teoh1, R. Parekh1

    1Hospital for Sick Children, Toronto, ON, Canada, 2Royal Hospital for Children, Glasgow, United Kingdom, 3St. Michael’s Hospital, Toronto, ON, Canada, 4University of Toronto, Toronto, ON, Canada, 5Mount Sinai Hospital, Toronto, ON, Canada, 6E. M. Uleryk Consulting, Toronto, ON, Canada

    *Purpose: Calcineurin inhibitors (CNI) are standard of care immunosuppressants among all solid organ transplant (SOT) recipients, and the most common side effect is nephrotoxicity. There…
  • 1
  • 2
  • 3
  • …
  • 16
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences